Loading...
Market
What will be the outcome of Rezolute's RZ358 Phase 3 trial by end of 2024?
2
Resolution / Starting Odds
Primary endpoint met with significant improvement • 25%
Primary endpoint met with moderate improvement • 25%
Primary endpoint not met • 25%
Trial inconclusive or delayed • 25%
Rezolute Inc official press releases or FDA announcements
Story
FDA Lifts Partial Hold on Rezolute's Phase 3 Treatment for Congenital Hyperinsulinism
Sep 9, 2024, 12:00 PM
Rezolute Inc announced on Monday that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on its experimental treatment, RZ358, for congenital hyperinsulinism. This decision allows the inclusion of U.S. participants in the ongoing Phase 3 study. The treatment aims to address low blood sugar levels associated with the condition.
View original story
Similar markets
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Yes • 50%
No • 50%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Yes • 50%
No • 50%
Clinical hold • 25%
No action • 25%
Request for additional data • 25%
Other • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Less than 30% • 25%
30% to 49% • 25%
50% to 69% • 25%
70% or higher • 25%
Positive results • 33%
Negative results • 33%
Inconclusive results • 34%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Successful with superior efficacy • 25%
Successful with comparable efficacy • 25%
Unsuccessful • 25%
Trial inconclusive • 25%